We use cookies to ensure that we give you the best experience on our website. If you continue browsing our
website without changing your settings, we will assume that you are happy to receive all cookies on our site.

You can visit our Cookie Policy page to learn more about cookies and how to disable them, should you wish to withdraw your consent. Our Cookie Policy page explains what cookies are, lists the cookies used on this website, and outlines how you can manage them.

Subscribe to our regular email newsletter

Before you go...

Please give us your feedback on our site:

How useful was the site to
you today?

Neuropathic pain


See more topics

10 items

Research update: Oxycodone/naloxone compared with tapentadol for low back pain with a neuropathic component in an open-label study

Dr Karen H Simpson presents the findings of a 12-week study by Ueberall and Mueller-Schwefe comparing oxycodone/naloxone with tapentadol for chronic low back pain with a neuropathic component

Neuropathic pain: an unmet clinical need

Dr Nadine Attal, associate professor of neurology, reviews the recently updated evidence-based recommendations for pharmacotherapy of neuropathic pain

Research update: central neuropathic pain syndromes

Dr Karen H Simpson, pain specialist and joint editor, looks at a review of these complex, challenging pain conditions

Cannabis and pain management: what does the future have in store?

Cannabinoids have considerable potential to treat neuropathic pain and other chronic pain states, but the development of cannabis-derived treatments is hampered by a number of factors, writes Dr Mark A Ware

Buprenorphine: a review of pharmacology

Buprenorphine is a complex molecule associated with a number of myths about its pharmacology and mechanism of action, write Professor Robert Raffa and Dr Joseph Pergolizzi

Join in

Have a question? Ask an expert Join our experts: Become a contributor Share your experience: Submit a case study Get in touch: Contact us